EN DE
Watch enGene Holdings Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

enGene Holdings Inc. (ENGN) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of enGene Holdings Inc. stock $1.79, price $1.77, upside +1.1%, quality 25 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA29286X1015

EH enGene Holdings Inc. logo Thin data Nov 10, 2026

enGene Holdings Inc.

ENGN · US
Low Priority

The stock costs about what our calculation considers fair.

Low debt
Fair value $1.79 · Fairly valued
Mixed vs. peers (4/8)
Insiders bought $10,051 (6M)
Quality 25/100
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch enGene Holdings Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$28.44 $1.44 Fair Value $1.79 Feb 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

57‑month range $1.44 – $28.44 · fair‑value band $1.34 – $2.24 · the $1.77 price screens below the $1.79 fair value. As of Nov 10, 2026.

Follow enGene Holdings Inc. Common Stock in your weekly email

Every Wednesday you see whether enGene Holdings Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Show moreShow less

Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Stock analysis

enGene Holdings Inc. (ENGN) currently trades at $1.77, while our estimate is $1.79, so the stock looks roughly fairly valued today (gap 1.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.34 (bear) to $2.24 (bull), the price of $1.77 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

enGene Holdings Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$117M in FY2025.

Key figures

Market cap $123M Micro · EPS (TTM) $−2.07 · Return on equity −60.5% · Return on assets (EBIT) −26.5% (5-year average) · Free cash flow −$101M · Net cash $18.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 85% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 1%, ENGN screens cheaper than that median.

Fair Value

Bear $1.34 Fair Value $1.79 Bull $2.24
Price $1.77 · Upside +1.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 29
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $10,051, on Sep 22, 2026.

  • BuyWilliam GrossmanInterim Chief Medical Officer, Director5,102 shares at $1.97$10,051Sep 22, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ENGN, get fair value alerts →

Compare enGene Holdings Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 867 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside +1.1% · Top 25%
Profitability
Return on assets −53.0% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.74× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)35 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 19

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs ENGN
Samsung Biologics Co 207940 1,510,000 KRW 1,661,000 KRW +10% vs ENGN
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs ENGN
Genmab A/S GMAB kr 3,661 kr 3,880 +6% vs ENGN
argenx SE ARGX $962.27 $908.40 −6% vs ENGN
CSL Limited CSL A$200.73 A$181.40 −10% vs ENGN
BeOne Medicines AG 6160 HK$248.20 HK$152.80 −38% vs ENGN
Roivant Sciences Ltd ROIV $40.67 $17.39 −57% vs ENGN
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs ENGN
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs ENGN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

enGene Holdings Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "enGene Holdings Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/ENGN

Frequently asked questions

Is enGene Holdings Inc. (ENGN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.79 versus a price of $1.77, about +1% upside (fairly valued).
What is the fair value of ENGN?
Our estimate for enGene Holdings Inc. is $1.79 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.77.
What is the quality score of ENGN?
enGene Holdings Inc. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for enGene Holdings Inc. (ENGN)?
Our calculated price target is the estimate of $1.79 (as of Nov 10, 2026). Cautious scenario $1.34, optimistic scenario $2.24. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the enGene Holdings Inc. Common Stock stock forecast for 2026?
Our estimate puts fair value at $1.79, about +1% upside versus a price of $1.77 (fairly valued). Cautious scenario $1.34, optimistic scenario $2.24. The calculation is refreshed regularly with new filings.
What is the intrinsic value of enGene Holdings Inc. (ENGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For enGene Holdings Inc. it is $1.79 per share (as of Nov 10, 2026), against a price of $1.77.
Is enGene Holdings Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ENGN trades below its calculated fair value: price $1.77, fair value $1.79, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENGN?
No. The price is what the market pays today ($1.77); the fair value is what the company's own numbers justify ($1.79). For enGene Holdings Inc. the two are $0.0200 per share apart. That gap is exactly why we show both numbers side by side.
How much is enGene Holdings Inc. Common Stock worth?
The market values enGene Holdings Inc. at about $123M (market capitalisation, as of Nov 10, 2026). Per share that is $1.77; our models calculate a fair value of $1.79 per share.
What do the bullish and bearish scenarios say about ENGN?
Our models span a range for enGene Holdings Inc.: cautious scenario $1.34, base $1.79, optimistic $2.24 per share (as of Nov 10, 2026, price $1.77). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of enGene Holdings Inc. (ENGN)?
Balance-sheet figures for enGene Holdings Inc. (as of Nov 10, 2026): return on equity −60.5%, debt of 0.09 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is ENGN from its 52-week high?
enGene Holdings Inc. trades at $1.77, about 85% below its 52-week high of $12.17 and 23% above the low of $1.44 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $1.79 is for.
Which stocks are comparable to enGene Holdings Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is enGene Holdings Inc. Common Stock stock attractive at the current price?
The data as of Nov 10, 2026: price $1.77, calculated fair value $1.79 (+1%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. enGene Holdings Inc. currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of enGene Holdings Inc. (ENGN)?
The closing price on Nov 9, 2026 was $1.77. Our estimate is $1.79, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with enGene Holdings Inc. Common Stock right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of enGene Holdings Inc.

How large is the market capitalisation of enGene Holdings Inc. (ENGN)?
The market capitalisation of enGene Holdings Inc. is $123M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of enGene Holdings Inc. (ENGN)?
Earnings per share at enGene Holdings Inc. are $−2.07. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of enGene Holdings Inc. (ENGN)?
The return on equity (ROE) of enGene Holdings Inc. is −60.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of enGene Holdings Inc. (ENGN)?
On an EBIT basis the return on assets of enGene Holdings Inc. is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does enGene Holdings Inc. (ENGN) generate?
The free cash flow of enGene Holdings Inc. is −$101M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does enGene Holdings Inc. (ENGN) hold?
enGene Holdings Inc. holds more cash than debt, $18.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch enGene Holdings Inc. Common Stock in the live analysis

One click puts enGene Holdings Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.